

1 2 3 4 5 6 7 8 14 18 19 20 21 22

chain bonds :

1-11 2-16 11-12 11-13 13-14 13-17 22-23

ring bonds :

1-2 1-5 2-3 3-4 3-6 4-5 4-8 6-7 7-8 14-18 14-22 18-19 19-20 20-21 21-22

exact/norm bonds :

1-2 1-5 1-11 2-3 2-16 3-4 3-6 4-5 4-8 6-7 7-8 11-12 11-13 13-14 13-17 14-18 14-22 18-19 19-20 20-21 21-22 22-23

G1:C,S

G2:H,CH3

G3:C,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 11:CLASS 12:CLASS
13:CLASS 14:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 C,S

G2 H,Me

G3 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 12:54:36 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 554 TO ITERATE

100.0% PROCESSED 554 ITERATIONS
SEARCH TIME: 00.00.01

83 ANSWERS

L2 83 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 12:54:42 ON 15 FEB 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Feb 2006 VOL 144 ISS 8

FILE LAST UPDATED: 14 Feb 2006 (20060214/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l2

L3 4 L2

=> d ibib abs hitstr 1-4

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

ACCESSION NUMBER: 2005:216670 CAPLUS

DOCUMENT NUMBER: 142:298003

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2005020987 A1 20050310 WO 2004-GB3648 20040827

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, GR, GU, HK, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SN, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPL. INFO.: GB 2003-20422 A 20030830

OTHER SOURCE(S):


MARPAT 142:298003

GI




AB Title compds. represented by the formula I [wherein B = (un)substituted pyrrolyl-2-carboxyl or indolyl-2-carboxyl; R1 = independently halo, nitro,

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847684-49-5 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,6-naphthyridin-3-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 847684-50-8 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,6-naphthyridin-3-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

carbamoyl, alkanoyloxy, etc., R2 = H, (hydroxy)alkyl, alkylcarbamoyl, etc.; A = pyridylene ring; n = 0 or 1; and pharmaceutically acceptable salts or prodrugs thereof) were prep. as glycogen phosphorylase inhibitors. For example, II was given in a multi-step synthesis starting from

4,5-dichlorothiophene-2-carboxaldehyde. II showed thermodyn. soly. (16.2 μM) and plasma-protein binding activity with 0.06 μM. Thus, I and their pharmaceutical compns. are useful as glycogen phosphorylase inhibitors for the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinemia, hyperglucagonemia, cardiac ischemia or obesity in a warm-blooded animal, such as man (no data).

IT 847684-47-3P 847684-48-4P 847684-49-5P


847684-50-8P 847684-51-9P 847684-52-0P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)

RN 847684-47-3 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,5-naphthyridin-3-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 847684-48-4 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,5-naphthyridin-3-yl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847684-51-9 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,8-naphthyridin-3-yl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 847684-52-0 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,8-naphthyridin-3-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




IT 847684-45-1P 847684-46-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)


RN 847684-45-1 CAPLUS

CN 1,5-Naphthyridine-1(2H)-acetic acid, 3-[[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847684-46-2 CAPLUS
CN 1,5-Naphthyridine-1(2H)-acetic acid, 3-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonylamino]-3,4-dihydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)




IT 600157-44-6P 600157-52-6P 600157-53-7P
847684-40-6P 847684-41-7P 847684-42-8P
847684-43-9P 847684-44-0P 847684-53-1P
847684-54-2P 847684-55-3P 847684-56-4P
847684-57-5P 847684-58-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)
RN 600157-44-6 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinoliny]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847684-41-7 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-1-(3-hydroxypropyl)-2-oxo-1,5-naphthyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 847684-42-8 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2-oxo-1,6-naphthyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 847684-43-9 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2-oxo-1,5-naphthyridin-3-yl)]- (9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-52-6 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-2-oxo-1,5-naphthyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 600157-53-7 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 847684-40-6 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-1-(3-hydroxypropyl)-2-oxo-1,5-naphthyridin-3-yl)]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 847684-44-0 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2-oxo-1,5-naphthyridin-3-yl)]- (9CI) (CA INDEX NAME)



RN 847684-53-1 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-1-(2-(methylsulfonyl)ethyl)-2-oxo-1,5-naphthyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 847684-54-2 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-1-(2-(methylsulfonyl)ethyl)-2-oxo-1,5-naphthyridin-3-yl)]- (9CI) (CA INDEX NAME)



RN 847684-55-3 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl)]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 847684-56-4 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847684-57-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-2-oxo-1,8-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 847684-74-6P 847684-75-7P 847684-76-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)
 RN 847684-74-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847684-75-7 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1,2,3,4-tetrahydro-1-[2-(methylthio)ethyl]-2-oxo-1,5-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847684-58-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-2-oxo-1,6-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 847684-72-4P 847684-73-5P
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)
 RN 847684-72-4 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847684-73-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847684-76-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-1-[2-(methylthio)ethyl]-2-oxo-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

FORMAT

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:589248 CAPLUS
 DOCUMENT NUMBER: 141:140474
 TITLE: Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
 INVENTOR(S): Sher, Philip M.; Ellsworth, Bruce A.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 43 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004142938	A1	20040722	US 2003-712823	20031113
PRIORITY APPLN. INFO.:			US 2002-426465P	P 20021114

OTHER SOURCE(S): MARPAT 141:140474
 GI




AB Prodrugs of glycogen phosphorylase inhibiting compds. are provided, said prodrug compds., G(-O2CR')m(-OH)n(-O2C(CH2)pCH3)q [G = branched or straight C3-5-carbon chain and (-O2CR'), (-OH) and (-O2C(CH2)pCH3) are attached to any available carbon atom along G; m = 1 - 4; n = 0 - 3; p = 0 - 16; q = 0 - 3; where m + n + q = 3 or 4; and -O2CR' is a fragment of a compound I wherein W = W1, W2, W3; X = O, S, SO2, CHR5, , CHR5O, CHR5S, CHR5SO2, CHR5CO, CH2CHR5; Y = bond, CHR6; Z = aryl, heteroaryl; R1 = H, alkyl, alkenyl; R2 = H, alkyl, aryl, arylalkyl, heteroarylalkyl, alkenyl; R3, R4 = H, halo, CF3, CN, alkyl, alkoxy; R5, R6 = H, alkyl, aryl, alkenyl, CN, CN4R9A (tetrazole), CO2R9A, CONR9AR9B, CONR9AOR9B; A = CH,


L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 B = O, S; wherein R1, R2, R5, R6, R7, R8 = alkyl, aryl, alkenyl, arylalkyl, heteroarylalkyl, alkoxy, aryloxy and each may be substituted with 1 - 3 hydrogen bonding groups). Thus, 3-[(5-chloroindolecarbonyl)amino]-3,4-dihydrocarboxytril I (R1 = R2 = H, W = 5-chloroindole, X = CH2, YZ = benzo) was prepd. from 3-amino-3,4-dihydrocarboxytril via acylation with 5-chloroindolecarboxylic acid resin-bound 2,3,5,6-tetrafluorophenyl ester. Further provided are pharmaceutical compns. and methods for treating diabetes and related diseases employing compds. above, either alone or in combination with another therapeutic agent.

IT 724783-28-2P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compds.)

RN 724783-28-2 CAPLUS
 CN 4-Quinoloneacetic acid, 3-[[[(2-bromo-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-1,2,3,4-tetrahydro-2-oxo-, 1,2,3-propanetriyl ester, (3R,3'R,3''R,4S,4'S,4''S)- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 PAGE 1-B





L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:719489 CAPLUS
 DOCUMENT NUMBER: 139:261278
 TITLE: Preparation of heterocyclic amides as inhibitors of glycogen phosphorylase
 INVENTOR(S): Birch, Alan Martin; Morley, Andrew David; Stocker, Andrew; Whittamore, Paul Robert Owen
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 126 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074532	A1	20030912	WO 2003-GB877	20030304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GN, KE, LS, MW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477667	AA	20030912	CA 2003-2477667	20030304
AU 2003214377	A1	20030916	AU 2003-214377	20030304
BR 2003008146	A	20041207	BR 2003-8146	20030304
EP 1483270	A1	20041208	EP 2003-74941	20030304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, SK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005131015	A1	20050616	US 2003-506741	20030304
JP 2005526058	T2	20050908	JP 2003-573000	20030304
NO 2004003852	A	20040914	NO 2004-3852	20040914
PRIORITY APPLN. INFO.:			GB 2002-5165	A 20020306
			WO 2003-GB877	W 20030304

OTHER SOURCE(S): MARPAT 139:261278
 GI

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The title compds. [I; X = N, CH; R4 and R5 together are either SCR6:CR7 or CR7:CR6S; R6, R7 = H, halo, alkyl, etc.; A = phenylene or heteroarylene; n


= 0-2; R1 = halo, NO2, CN, OH, CO2H, etc.; R2 = H, OH, CO2H; R3 = H, OH, aryl, heterocyclyl, etc.] which possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity such as diabetes

type II, were prepared. Thus, amidation of 5-carboxy-2-chloro-6H-thieno[2,3-b]pyrrole with Me (3-amino-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetate (preps. given) in the presence of HOBt and EDCI in DMF afforded 76% II. The compds. I showed IC50 values in the range 100nM to 1nM against hrl glycogen phosphorylase a (hrl GPa). Pharmaceutical composition comprising the compound I was claimed.


IT 600157-07-1P 600157-08-2P 600157-16-2P
600157-18-4P 600157-23-1P 600157-26-4P
600157-27-5P 600157-28-6P 600157-32-2P
600157-38-8P 600157-41-3P 600157-42-4P
600157-47-9P 600157-49-1P 600653-76-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of thienopyrrolecarboxamides as inhibitors of glycogen phosphorylase)

RN 600157-07-1 CAPLUS
CN 1(2H)-Quinolineacetic acid, 3-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-08-2 CAPLUS
CN 1(2H)-Quinolineacetic acid, 3-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 600157-16-2 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 600157-18-4 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-23-1 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-2-oxo-1-[2-oxo-2-[(3aR,6aS)-tetrahydro-2,2-dimethyl-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethyl]-3-quinolinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 600157-26-4 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[(2,2-dimethyl-1,3-dioxan-5-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-27-5 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)propyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-28-6 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1-[(2,2-dimethyl-1,3-dioxan-5-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 600157-32-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[1-(cyanomethyl)-1,2,3,4-
 tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)



RN 600157-38-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[1,2,3,4-tetrahydro-1-[2-
 (methylthio)ethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-41-3 CAPLUS
 CN 1(2H)-Quinolineacetic acid, 3-[[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-
 yl)carbonyl]amino]-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX
 NAME)



RN 600157-42-4 CAPLUS
 CN 1(2H)-Quinolineacetic acid, 3-[[[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-
 yl)carbonyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 600157-09-3P 600157-10-6P 600157-11-7P
 600157-12-8P 600157-13-9P 600157-14-0P
 600157-15-1P 600157-17-3P 600157-19-5P
 600157-20-8P 600157-21-9P 600157-22-0P
 600157-24-2P 600157-25-3P 600157-29-7P
 600157-30-0P 600157-31-1P 600157-33-3P
 600157-34-4P 600157-35-5P 600157-36-6P
 600157-37-7P 600157-39-9P 600157-40-2P
 600157-43-5P 600157-44-6P 600157-45-7P
 600157-46-8P 600157-48-0P 600157-50-4P
 600157-52-6P 600157-53-7P 600157-54-8P
 600157-55-9P 600157-73-1P 600157-74-2P

RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of thienopyrrolecarboxamides as inhibitors of glycogen
 phosphorylase)



RN 600157-09-3 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-10-6 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonyl]amino]-3,4-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 600157-47-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[1,2,3,4-tetrahydro-1-(3-
 hydroxypropyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-49-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-2-
 oxo-1-(2-oxobutyl)-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600653-76-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[1-[(2Z)-2-amino-2-
 (hydroxyimino)ethyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]-2-chloro-
 (9CI) (CA INDEX NAME)




L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-11-7 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonyl]amino]-3,4-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-12-8 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonyl]amino]-3,4-dihydro-N-hydroxy-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-13-9 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonyl]amino]-3,4-dihydro-N-(2-hydroxyethyl)-2-oxo- (9CI) (CA INDEX
 NAME)




L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-14-0 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[(1,2,3,4-tetrahydro-1-(2-
 hydroxyethyl)-2-oxo-3-quinolinyl)]- (9CI) (CA INDEX NAME)




RN 600157-15-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[(1,2,3-dihydroxypropyl)-
 1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-17-3 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(3R)-1-[(2S)-2,3-
 dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-21-9 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonylamino]-3,4-dihydro-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-2-oxo-
 (9CI) (CA INDEX NAME)




RN 600157-22-0 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonylamino]-3,4-dihydro-N-(2-methoxyethyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-24-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-(2-[(3R,4S)-3,4-]]

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-19-5 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(3R)-1-[(2R)-2,3-
 dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 600157-20-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[(1,2,3,4-tetrahydro-1-[2-
 (4-hydroxy-1-piperidinyl)-2-oxoethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-25-3 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-(2-
 (dimethylamino)ethyl)-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-29-7 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide,
 2,3-dichloro-N-[(1,2,3,4-tetrahydro-
 1-[3-hydroxy-2-(hydroxymethyl)propyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-30-0 CAPLUS


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1(2H)-Quinoloneacetamide, 3-[[[2-chloro-6H-thieno[2,3-b]pyrrol-5-yl]carbonyl]amino]-N-(2,3-dihydroxypropyl)-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-31-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-(2-methoxyethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-33-3 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-37-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[1-[(5-amino-1,3,4-oxadiazol-2-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 600157-39-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-(2-methylsulfinylethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-40-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-(2-methylsulfonyl)ethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 600157-34-4 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-2-oxo-1-(1H-tetrazol-5-ylmethyl)-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-35-5 CAPLUS
 CN 1(2H)-Quinoloneacetamide, 3-[[[2-chloro-6H-thieno[2,3-b]pyrrol-5-yl]carbonyl]amino]-3,4-dihydro-N-(methylsulfonyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-36-6 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-43-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-44-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1-(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 600157-45-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[3-(dimethylamino)-2-hydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-46-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(2S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-48-0 CAPLUS
 CN 1(2H)-Quinolinepropanamide, 3-[[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-3,4-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-50-4 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(2S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-73-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(2S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 600157-74-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(2S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 600157-56-0P 600157-59-3P 600157-61-7P

600157-63-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of thienopyrrolecarboxamides as inhibitors of glycogen phosphorylase)
 RN 600157-56-0 CAPLUS


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-52-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(2S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,5-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 600157-53-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(2S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-54-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(2S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-55-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(2S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(2S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)



RN 600157-59-3 CAPLUS
 CN 1(2H)-Quinolineacetic acid, 3-[[[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonyl]amino]-3,4-dihydro-2-oxo-, hydrazide (9CI) (CA INDEX NAME)




RN 600157-61-7 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(2S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

C 07 D 215/38
 546/156
 514/312
 A61 K 31/4704
 C 07 D 471/04
 546/122
 514/300
 A61 K 31/4375

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-63-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,1-dimethylethyl)dimethylsilyl]oxypropyl-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2002:185126 CAPLUS
 DOCUMENT NUMBER: 136:247485
 TITLE: Preparation of bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
 INVENTOR(S): Bartlett, Julie B.; Freeman, Sue; Kenny, Peter; Morley, Andrew; Whittamore, Paul
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
 SOURCE: PCT Int. Appl., 141 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020530	A1	20020314	WO 2001-SE1880	20010831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2417594	A1	20020314	CA 2001-2417594	20010831
AU 2001082833	A5	20020322	AU 2001-82833	20010831
EP 1317459	A1	20030611	EP 2001-961577	20010831
EP 1317459	B1	20040407		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013606	A	20030624	BR 2001-13606	20010831
JP 20040508376	T2	20040318	JP 2002-525151	20010831
AT 263772	E	20040415	AT 2001-961577	20010831
NZ 524011	A	20040827	NZ 2001-524011	20010831
PT 1317459	T	20040831	PT 2001-961577	20010831
ES 2217183	T3	20041101	ES 2001-1961577	20010831
EE 200300083	A	20041215	EE 2003-83	20010831
ZA 2003001013	A	20040505	ZA 2003-1013	20030205
US 2003232875	A1	20031218	US 2003-344506	20030210
NO 2003001024	A	20030305	NO 2003-1024	20030305
BG 107624	A	20040130	BG 2003-107624	20030310
HK 1055299	A1	20041021	HK 2003-107519	20031016
PRIORITY APPLN. INFO.:			GB 2000-21831	A 20000906
			WO 2001-SE1880	W 20010831

OTHER SOURCE(S): MARPAT 136:247485
 GI

10/344506
 4 pending

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Title compds. I [R1 = H, halo, NO2, CN, OH, (un)substituted alkyl, alkenyl, etc.; R2 = H, halo, NO2, CH2F, CHF2, CF3, amino, alkyl, alkenyl, alkoxy, etc.; R3 = H, alkyl; -X-Y-Z- is selected from -S-CR4=CR5-, -CR4=CR5-S-, -O-CR4=CR5-, -CR4=CR5-O-, -N-CR4-S-, -S-CR4=N-, -NR3-CR4=CR5- and -CR4=CR5-NR3- wherein R4 and R5 = independently H, halo, CN, alkyl, ureido, NO2, etc.; n = 0-4] or a pharmaceutically acceptable salt or an

in vivo hydrolyzable ester thereof were prepared possessing glycogen phosphorylase inhibitory activity (no data). Thus, II was prepared by amidation of 5-carboxy-2,3-dichloro-4H-thieno[3,2-b]pyrrole with 2-phenoxylethylamine. As glycogen phosphorylase inhibitors, I have value in the treatment of disease states associated with increased glycogen phosphorylase activity, e.g., type 2 diabetes. Pharmaceutical compns. containing I are described.

IT 403859-70-1P 403859-94-9P 403859-96-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(target compound: preparation of thienopyrrolyl amides as glycogen phosphorylase inhibitors)
 RN 403859-70-1 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)



RN 403859-94-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-(1,2,3,4-tetrahydro-2-

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

exo-3-quinolinyl)- (9CI) (CA INDEX NAME)



RN 403859-96-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

These 3 compounds
 are proviso-out.